On April 7, 2024, Fosun Pharma (SSE: 600196, HKEX: 02196) released its 2024 ESG and Sustainability Report (referred to as the "Report"), marking the 17th consecutive year the Company has demonstrated its ESG practices and achievements in environmental protection, social responsibility, and corporate governance to stakeholders.

Nowadays, high-quality development has become a consensus and proactive pursuit across society. The adoption and implementation of ESG principles have emerged as a powerful catalyst for sustainable, high-quality economic and social progress.As a leading innovation-driven global healthcare Company , Fosun Pharma remains steadfast in its mission to enable "Better Health for Families Worldwide." By deeply integrating ESG concepts into its corporate strategy and daily operations, Fosun Pharma actively advances ESG practices, contributing to thehigh-quality development of the industry and even the society.

In April 2024, the Shanghai Stock Exchange (SSE) issued theSelf-Regulatory Guidelines No.14 forListed Companies—Sustainability Report (Trial)(referred to asthe "Guidelines") to promote high-quality development and investment value among listed companies while standardizing sustainability reporting.As a dual-listed Company in both A-share and H-share markets, Fosun Pharma has identified 14 material topics under the Guidelines, of which 4 topics are double materiality topics including innovation-driven growth, product and service safety and quality, environmental management, and coping with climate change. In addition to strengthening ESG information disclosure, Fosun Pharma also ensures that the Report complies with theEnvironmental, Social and Governance Reporting Codeset out in Appendix C2 to the Hong Kong Stock Exchange Listing Rules and theGlobal Reporting Initiative (GRI) Standards(2021 edition, referred to as "GRI Standards") of the Global Sustainability Standards Board (GSSB).

In 2024, Fosun Pharma demonstrated outstanding ESG performance, maintaining its MSCI ESG Rating of "A" and Hang Seng ESG Rating of "A-." The Company also earned multiple prestigious accolades, including a spot on the 2024 China ESG 50 list (Forbes) and the list of 100 ESG Pioneers Among Listed Companies in China (China Media Group). Notably, Fosun Pharma’s Rural Doctor Project was recognized as one of the “Outstanding Rural Revitalization Practices of Public Companies in 2024” by the China Association for Public Companies in January 2025. This accolade underscores the project’s contribution to strengthening grassroots healthcare and empowering rural doctors over the years, reflecting Fosun Pharma’s steadfast commitment to corporate social responsibility within the pharmaceutical sector.

Fosun Pharma has always regarded innovation as its most critical social responsibility. Focusing on unmet clinical needs, the Company continuously enhances drug accessibility and affordability through diversified innovation models such as in-house R&D and licensed technology introduction, driving global health equity.With a long-standing commitment to improving healthcare in developing countries, Fosun Pharma has implemented comprehensive initiatives across Africa through sustainable medicine supply chains, clinical skills training programs, localized pharmaceutical production. These efforts are designed to support healthcare infrastructure construction in developing countries, as well as the development of public health capacity.

Fosun Pharma has actively responded to the national rural revitalization strategy, and has made significant contributions through its "Fosun Care 121" Special Fund. Its in-depth participation in the Rural Doctor Project has supported 25,000 village doctors, benefiting approximately 3 million rural households. Additionally, the Pink Blue Ribbon Charity Initiative has provided cervical and breast cancer screening for over 16,000 women across Yunnan and Sichuan, substantially improving grassroots healthcare capabilities. Over the past three years, Fosun Pharma's cumulative charitable donations have exceeded RMB 300 million.

In the field of environmental protection, Fosun Pharma remains committed to green development and the "dual carbon" strategy. The Company actively addresses climate change challenges while fostering harmonious development of business, society, and the environment, with the goal of collectively creating a beautiful green home. In 2024, the Company invested approximately RMB 110 million in environmental protection initiatives.

ESG is becoming an important investment consideration for the capital markets, and domestic regulators are placing increasing emphasis on ESG.Fosun Pharma attaches great importance to the long-term ESG governance capability. The Company has establishedan ESG governance structure comprising the Board of Directors, the ESG Committee of the Board, the ESG Management Committee, and the ESG Working Group to ensure effective oversight, scientific guidance, and full support for sustainable development from both the Board and management.

Wu Yifang, Chairman of Fosun Pharma, said, "2024 is a year in which Fosun Pharma Group has made significant progress in the field of ESG. In the future,we will continue to proactively implement ESG principles, steadfastly pursue innovation-driven development, deliver safe and effective high-quality products, advance global health initiatives, and creating better health for families worldwide."